Anika Therapeutics Inc.
Anika Therapeutics develops and commercializes products based on hyaluronic acid technology. They offer OA pain management products like Monovisc, Orthovisc, and Cingal for osteoarthritis relief. The company also has a joint preservation and restoration product family including Hyalofast, Tactoset, and others. Additionally, they have non-orthopedic products such as veterinary, anti-adhesion barrier, burn treatment, and ophthalmic products. Founded in 1983, the company is headquartered in Bedford, Massachusetts.
Overview
Strengths
- Price to book ratio (1.06) is lower than the sector mean (733.70).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (3.00%) is significantly lower than the sector mean (14.71%).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (2.52%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 43.4 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 3.0% |
| Net Debt/EBITDA | 100.0 |